Clobetasol Propionate Spray Followed by Calcitriol Ointment Effective for Plaque Psoriasis: Presented at AAD
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Clobetasol Propionate Spray Followed by Calcitriol Ointment Effective for Plaque Psoriasis: Presented at AAD

By Jill Stein

SAN FRANCISCO -- March 9, 2009 -- Clobetasol propionate (CP) 0.05% spray followed by calcitriol ointment is effective and well tolerated for the management of moderate to severe plaque psoriasis, researchers stated here at the American Academy of Dermatology (AAD) 67th Annual Meeting.

Mark Lebwohl, MD, Dermatology Division, Mount Sinai School of Medicine, New York, New York, and colleagues presented the results of the multicentre, open-label study here on March 6 in a poster presentation.

Topical therapy has been the first-line of defence against psoriasis, but there is currently a shift from a focus on short-term treatment of disease outbreaks to maintenance of long-term control, researchers explained.

The researchers therefore tested the efficacy and safety of a consecutive treatment regimen of twice-daily CP spray for up to 4 weeks followed by twice-daily calcitriol ointment 3 mcg/g for up to 8 weeks.

The study enrolled 300 patients but the researcher presented results of an analysis of 161 patients that made up the modified intent-to-treat population.

Overall, 119 (73.9%) patients achieved treatment success after 12 weeks of treatment. Treatment success was defined as at least 1 grade improvement in the overall disease severity score from baseline to week 12.

The treatment regimen was generally well tolerated with 91 adverse events reported in 49 patients (27.8%) at the time of the interim analysis. Of these, about 33% were severe and 16.5% were thought to be possibly or likely related to the study medication.

The most commonly reported cutaneous irritations were mild to moderate pruritus, stinging and burning, and telangiectasia. There were no cases of skin atrophy, and folliculitis was present in 1 patient in the safety population at week 12 compared with 2 reports at enrolment.

The results of the study combined with results from earlier trials support the use of a consecutive treatment regimen of CP spray followed by calcitriol ointment for moderate to severe plaque psoriasis, the researchers concluded.

The study was supported by Galderma Laboratories, L.P.

[Presentation title: A Consecutive Treatment Regimen of Clobetasol Propionate 0.05% Spray Followed by Calcitriol Ointment 3 mcg/g for the Management of Moderate to Severe Plaque Psoriasis. Abstract P3362]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities